Thursday, May 7, 2020
CONTINENTAL BREAKFAST
7:00 - 8:00  
Introduction
8:00 - 8:15

Introduction to the Day’s Proceedings

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada


Remembering Henry Lynch

Lisa Madlensky, PhD, CGC, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA



SESSION 5:
Early diagnosis of breast and prostate cancer in BRCA1 or BRCA2 heterozygotes
8:15 - 9:45

CHAIR: Jeffrey Weitzel, MD, City of Hope National Medical Center, Duarte, CA, USA

8:15 - 8:35

MRI and the early diagnosis of breast cancer in BRCA1 and BRCA2 heterozygotes

Steven Narod, MD, FRCPC, FRSC, Canada Research Chair in Breast Cancer, Women’s College Research Institute, Toronto, ON, Canada

8:35 - 8:55

Prostate cancer in men with BRCA1 or BRCA2 pathogenic variants - the IMPACT STUDY

Elena Castro, MD, PhD, CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain

8:55 - 9:05

Proffered paper 1

9:05 - 9:15

Proffered paper 2

9:15 - 9:25

Proffered paper 3

9:25 - 9:45

Question and discussion period (all speakers)

BREAK
9:45 - 10:15  
SESSION 6:
New developments in cancer treatment in HBOC
10:15 - 11:45

CHAIR: Ephrat Levy-Lahad, MD, Shaare Zedek Medical Center, Jerusalem, Israel

10:15 - 10:35

Update on therapy for breast cancer for women with BRCA1/2 pathogenic variants

Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

10:35 - 10:55

New treatments for BRCA-deficient ovarian cancer

Ursula Matulonis, MD Dana-Farber Cancer Institute, Boston, MA, USA

10:55 - 11:05

Proffered paper 1

11:05 - 11:15

Proffered paper 2

11:15 - 11:25

Proffered paper 3

11:25 - 11:45

Question and discussion period (all speakers)

LUNCH
11:45 - 13:15  


Sponsored Symposium (TBD)

11:45 - 13:15  

SESSION 7:
Genetic counselling – New challenges
13:15 - 14:45

CHAIR: Antonis Antoniou PhD, University of Cambridge, Cambridge, UK

13:15 - 13:35

Genetic Counseling for a general population: lessons learned

Lauren Ryan, MS, LCGC, Color, Burlingame, CA, USA

13:35 - 13:55

A practical approach to handling direct-to-consumer data

Lisa Madlensky, PhD, CGC, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

13:55 - 14:05

Proffered paper 1

14:05 - 14:15

Proffered paper 2

14:15 - 14:25

Proffered paper 3

14:25 - 14:45

Question and discussion period (all speakers)

POSTER SESSION 2
14:45 - 16:30
SESSION 8:
Special Interest Groups (SIGs)
16:30 - 18:40

Moderated one-hour interactive discussions with the aim of fostering bilateral knowledge transfer. Participants will rank these SIGs in order of preference and will be assigned to participate in two SIGs on a first-come, first-reserved basis.

SIG 1:

Rarer moderate to highly penetrant breast and ovarian cancer syndromes – CDH1, PTEN, TP53, NTHL1 and others

In this session, attendees will join the presenters in exploring clinico-pathological aspects of a set of well-known and less well-known breast and ovarian cancer susceptibility genes. Dr. Tischkowitz will focus on CDH1, Dr. Hoogerbrugge on PTEN and NTHL1 and Dr. Weitzel will discuss TP53. Attendees will be encouraged to send in specific cases in advance for discussion at the SIG.

  • Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK (session lead)

  • Nicoline Hoogerbrugge, MD, PhD, Radboud University Medical Center, Nijmegen, The Netherlands

  • Jeffrey Weitzel, MD, City of Hope National Medical Center, Duarte, CA, USA

SIG 2:

Genetic counselling – How to expect the unexpected?

In this interactive case-based session, Dr. Hurley will explore advance concepts in genetic counselling and will show how counsellors can help clients cope with the challenges associated with discovering their genetic status.

  • Karen Hurley, PhD, Cleveland Clinic, Cleveland, OH, USA

SIG 3:

Hereditary prostate, pancreas and male breast cancer: Research updates and surveillance recommendations

In this session, the three presenters will discuss the latest research on prevention, early diagnosis and treatment of three cancers that are associated with germline mutations in HRD genes. Attendees will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.

  • Elena Castro, MD, PhD, CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain

  • George Zogopoulos, MD, PhD, McGill University Health Centre, Montréal, QC, Canada

  • Justin Lorentz, CGC, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

SIG 4:

Moderate risk genes – When and where are they useful?

In this session, the four experts will discuss the role of clinical testing for moderate risk breast and ovarian cancer susceptibility genes. They will review data on the cancer risks associated with pathogenic variants in each of the major moderate risk genes (e.g. ATM, BARD1, BRIP1, CHEK2, RAD51C, RAD51D) and will discuss emerging candidate genes. Models to assess risk will be discussed, as will counseling challenges. The pathology of tumors associated with pathogenic variants in these genes will be considered.

  • Paul James, MD, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (session lead)

  • Mark Robson, MD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

  • Lisa Madlensky, PhD, CGC, Moores UCSD Cancer Center, University of California San Diego, La Jolla, CA, USA

  • Marjanka Schmidt, PhD, Netherlands Cancer Institute, Amsterdam, and Leiden University Medical Center, Leiden, The Netherlands

SIG 5:

Ethico-legal issues around usage of genomic data

Some of the issues that will be discussed in this interactive session include genetic counselling in the private direct to consumer testing era, patenting of genes and its influence on data sharing, secrecy vs open innovation, ethical aspects of large-scale genomic sequencing and genetic discrimination. Attendees will be encouraged to send in specific ethics questions in advance for discussion at the SIG.

  • Yann Joly, PhD, AdE McGill University, Montréal, QC, Canada (session lead)

  • Gabrielle Bertier, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, USA

  • Nathalie Bolduc, MSc, Quebec Breast Cancer Foundation, Montréal, QC, Canada

  • Robert Cook-Deegan, MD, Arizona State University, Washington, DC, USA

SIG 6:

Ovarian cancer – a multi-faceted view

Ovarian cancer is one of the most preventable cancers. In this unique session, five leading experts will discuss the epidemiology of, and inherited contribution to, ovarian cancer, the role of risk assessment in management, the molecular genetics and pathology of the main subtypes of ovarian cancer, and where new treatments are taking the field.

  • Paul Pharoah, BM, BCh, PhD, University of Cambridge, Cambridge, UK (session lead)

  • Antonis Antoniou PhD, University of Cambridge, Cambridge, UK

  • Blaise Clarke, MD, University Health Network, Toronto, ON, Canada

  • Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA, USA

  • Britta Weigelt, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA